ex991.htm

Consolidated Financial Statements of

LORUS THERAPEUTICS INC.

Years ended May 31, 2010, 2009 and 2008

KPMG LLP

Chartered Accountants

Bay Adelaide Centre

333 Bay Street Suite 4600

Toronto ON M5H 2S5

Canada

Telephone

Fax

Internet

(416) 777-8500

(416) 777-8818

www.kpmg.ca

AUDITORS' REPORT TO THE SHAREHOLDERS

We have audited the consolidated balance sheets of Lorus Therapeutics Inc. as at May 31, 2010 and 2009 and the consolidated statements of operations and comprehensive income, deficit and cash flows for each of the years in the three-year period ended May 31, 2010 and for the period from inception on September 5, 1986 to May 31, 2010. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at May 31, 2010 and 2009 and the results of its operations and its cash flows for each of the years in the three-year period ended May 31, 2010 and for the period from inception on September 5, 1986 to May 31, 2010 in accordance with Canadian generally accepted accounting principles.

Chartered Accountants, Licensed Public Accountants

Toronto, Canada

August 23, 2010, except

as to note 18 which is

as of August 27, 2010

	KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG
	network of independent member firms affiliated with KPMG International Cooperative
	(“KPMG International”), a Swiss entity.
	KPMG Canada provides services to KPMG LLP.

LORUS THERAPEUTICS INC.

Consolidated Balance Sheets

(Expressed in thousands of Canadian dollars)

May 31, 2010 and 2009

	2010			2009

Assets

Current assets:
Cash and cash equivalents (notes 9 and 12)	$	667		$	5,374
Short-term investments (notes 4 and 9)		247			490
Prepaid expenses and other assets		636			826
		1,550			6,690

Fixed assets (note 5)		147			231
Goodwill		606			606

	$	2,303		$	7,527

Liabilities and Shareholders' Deficiency

Current liabilities:
Accounts payable	$	387		$	299
Accrued liabilities		1,458			1,131
Promissory note payable (note 17)		1,000			-
Secured convertible debentures (note 13)		-			14,448
		2,845			15,878

Shareholders' deficiency:
Share capital (note 6):
Common shares		163,920			162,240
Equity portion of secured convertible debentures (note 13)		-			3,814
Stock options		3,704			3,845
Contributed surplus		14,875			10,744
Warrants		1,039			417
Deficit accumulated during development stage		(184,080	)		(189,411	)
		(542	)		(8,351	)

Basis of presentation (note 1)
Contingencies, commitments and guarantees (note 14)
Subsequent events (note 18)

	$	2,303		$	7,527

See accompanying notes to consolidated financial statements.

On behalf of the Board:

"Denis R. Burger"		Director

"Aiping H. Young"		Director

LORUS THERAPEUTICS INC.

Consolidated Statements of Operations and Comprehensive Income

(Expressed in thousands of Canadian dollars, except for per common share data)

										Period from
										inception on
										September 5,
										1986 to
	Years ended May 31,									May 31,
	2010			2009			2008			2010

Revenue	$	131		$	184		$	43		$	1,171

Expenses:
Research and development (note 11)		2,517			3,757			6,260			126,514
General and administrative		2,964			2,958			3,715			60,839
Stock-based compensation (note 7)		176			446			719			8,594
Depreciation and amortization of fixed assets		86			189			317			9,817
Cost of sales		-			-			2			105
		5,743			7,350			11,013			205,869

Other expenses (income):
Interest expense		54			707			1,029			4,022
Accretion in carrying value of convertible debentures (note 13)		80			1,707			1,176			4,983
Amortization of deferred financing costs (note 13)		-			-			-			412
Interest income		(21	)		(270	)		(542	)		(12,257	)
		113			2,144			1,663			(2,840	)

Loss from operations		(5,725	)		(9,310	)		(12,633	)		(201,858	)

Gain on repurchase of convertible debentures and transfer of assets (note 13)		11,006			-			-			11,006
Gain on sale of shares (notes 1(b) and 14)		50			450			6,299			6,799

Net earnings (loss) for the period and other comprehensive income (loss)	$	5,331		$	(8,860	)	$	(6,334	)	$	(184,053	)

Basic and diluted earnings (loss) per common share	$	0.57		$	(1.08	)	$	(0.87	)

Weighted average number of common shares outstanding used in the calculation of (in thousands):
Basic earnings per share		9,364			8,236			7,169
Diluted earnings per share		9,379			8,236			7,169

See accompanying notes to consolidated financial statements.

LORUS THERAPEUTICS INC.

Consolidated Statements of Deficit

(Expressed in thousands of Canadian dollars)

										Period from
										inception on
										September 5,
										1986 to
	Years ended May 31,									May 31,
	2010			2009			2008			2010

Deficit, beginning of period:
As previously reported	$	(189,411	)	$	(180,551	)	$	(174,190	)	$	-
Change in accounting policy		-			-			(27	)		(27	)
As restated		(189,411	)		(180,551	)		(174,217	)		(27	)

Net earnings (loss) for the period		5,331			(8,860	)		(6,334	)		(184,053	)

Deficit, end of period	$	(184,080	)	$	(189,411	)	$	(180,551	)	$	(184,080	)

See accompanying notes to consolidated financial statements.

LORUS THERAPEUTICS INC.

Consolidated Statements of Cash Flows

(Expressed in thousands of Canadian dollars)

										Period from
										inception on
										September 5,
										1986 to
	Years ended May 31,									May 31,
	2010			2009			2008			2010

Cash flows from operating activities:
Net earnings (loss) for the period	$	5,331		$	(8,860	)	$	(6,334	)	$	(184,053	)
Items not involving cash:
Gain on repurchase of convertible debentures and transfer of assets (note 13)		(11,006	)		-			-			(11,006	)
Gain on sale of shares (note 1(b) and 14)		(50	)		(450	)		(6,299	)		(6,799	)
Stock-based compensation		176			446			719			8,594
Interest on convertible debentures		15			707			1,029			3,983
Accretion in carrying value of convertible debentures		80			1,707			1,176			4,983
Amortization of deferred financing costs		-			-			-			412
Depreciation, amortization and write-down of fixed assets and acquired patents and licenses		86			189			317			22,378
Other		(8	)		(10	)		(7	)		437
Change in non-cash operating working capital (note 12)		1,655			(942	)		(794	)		1,201
Cash used in operating activities		(3,721	)		(7,213	)		(10,193	)		(159,870	)

Cash flows from financing activities:
Issuance of debentures, net of issuance costs		-			-			-			12,948
Issuance (repurchase) of warrants		-						(252	)		37,153
Payment on settlement of convertible debentures, including transaction costs (note 13)		(3,521	)		-			-			(3,521	)
Proceeds on sale of shares, net of arrangement costs (note 1(b) and 14)		-			600			7,561			6,899
Issuance of common shares and warrants, net of issuance costs (note 6)		2,287			3,207			-			114,519
Cash provided by financing activities		(1,234	)		3,807			7,309			167,998

Cash flows from investing activities:
Maturity (purchase) of investments, net		250			6,304			4,189			(250	)
Business acquisition, net of cash received		-			-			-			(539	)
Acquired patents and licenses		-			-			-			(715	)
Additions to fixed assets		(2	)		(176	)		(58	)		(6,305	)
Proceeds on sale of fixed assets		-			-			-			348
Cash provided by (used in) investing activities		248			6,128			4,131			(7,461	)

Increase (decrease) in cash and cash equivalents		(4,707	)		2,722			1,247			667

Cash and cash equivalents, beginning of period		5,374			2,652			1,405			-

Cash and cash equivalents, end of period	$	667		$	5,374		$	2,652		$	667

Supplemental cash flow information (note 12)

See accompanying notes to consolidated financial statements.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

1.	Basis of presentation:

(a)

Going concern:

Lorus Therapeutics Inc. (the "Company") has not earned substantial revenue from its drug candidates and is therefore considered to be in the development stage. The continuation of the Company's research and development activities is dependent upon the Company's ability to successfully fund its cash requirements through a combination of equity financing and payments from strategic partners. The Company has no current sources of significant payments from strategic partners.

These consolidated financial statements have been prepared on a going concern basis in accordance with Canadian generally accepted accounting principles ("Canadian GAAP"). The going concern basis of presentation assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. There is significant doubt about the appropriateness of the use of the going concern basis because management has forecasted that the Company's current level of cash and cash equivalents and short-term investments, including the $4 million investment described in note 18, will not be sufficient to execute its current planned expenditures for the next 12 months without further investment. The Company is currently in discussion with several potential investors to provide additional funding. Management believes that it will complete one or more of these arrangements in sufficient time to continue to execute its planned expenditures without interruption. However, there can be no assurance that the capital will be available as necessary to meet these continuing expenditures, or if the capital is available, that it will be on terms acceptable to the Company. The issuance of common shares by the Company could result in significant dilution in the equity interest of existing shareholders. The Company is also considering alternatives to delay its research program until financing is available, amongst other cost savings measures. There can be no assurance that the Company will be able to obtain sufficient financing to meet future operational needs. As a result, there is a significant doubt as to whether the Company will be able to continue as a going concern and realize its assets and pay its liabilities as they fall due.

The consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis were not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets and liabilities, the reported revenue and expenses and the balance sheets classifications used.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

1.	Basis of presentation (continued):

(b)

Reorganization:

On November 1, 2006, the Company was incorporated as 6650309 Canada Inc. pursuant to the provisions of the Canada Business Corporation Act and did not carry out any active business from the date of incorporation to July 10, 2007. From its incorporation to July 10, 2007, the Company was a wholly owned subsidiary of 4325231 Canada Inc., formerly Lorus Therapeutics Inc. ("Old Lorus").

On July 10, 2007, the Company and Old Lorus completed a plan of arrangement and corporate reorganization (the "Arrangement"). As part of the Arrangement, all of the assets and liabilities of Old Lorus (including all of the shares of its subsidiaries held by it), with the exception of certain future tax assets were transferred, directly or indirectly, from Old Lorus to the Company. Securityholders in Old Lorus exchanged their securities in Old Lorus for equivalent securities in the Company (the "Exchange") and the board of directors and management of Old Lorus continued as the board of directors and management of the Company.

In connection with the Arrangement, the Company received cash consideration of approximately $8.5 million less an escrowed amount of $600 thousand related to the indemnification (received in July 2008), before transaction costs. After completion of the Arrangement, the Company is not related to Old Lorus, which was subsequently renamed Global Summit Real Estate Inc.

Under the Arrangement, the Company and its subsidiaries agreed to indemnify Old Lorus and its directors, officers and employees from and against all damages, losses, expenses (including fines and penalties), other third party costs and legal expenses, to which any of them may be subject arising out of various matters discussed in note 14.

As part of the Arrangement, the Company changed its name to Lorus Therapeutics Inc. and continued as a biopharmaceutical company, specializing in the research and development of pharmaceutical products and technologies for the management of cancer as a continuation of the business of Old Lorus.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

1.	Basis of presentation (continued):

The Arrangement has been accounted for on a continuity of interest basis and, accordingly, the consolidated financial statements of the Company reflect the financial position, results of operations and cash flows as if the Company has always carried on the business formerly carried on by Old Lorus. Consequently, all comparative figures presented in these consolidated financial statements include those of Old Lorus.

(c)

Share consolidation:

In accordance the authority granted by shareholders at the Company's annual and special meeting on November 30, 2009 to permit it to implement a consolidation of the Company's outstanding common shares in a ratio of between 1-for-10 and 1-for-50 at any time prior to November 30, 2010, the Company's Board of Directors approved a 1-for-30 share consolidation which became effective May 25, 2010. The share consolidation affects all of the Company's common shares, stock options and warrants outstanding at the effective time. Fractional shares were not issued. Prior to consolidation the Company had approximately 298 million shares outstanding. Following the share consolidation, the Company has approximately 9.9 million common shares outstanding. Similarly, prior to consolidation, the Company had approximately 20.2 million stock options and 36.9 million warrants to purchase common shares outstanding. Following the share consolidation, the Company had approximately 673 thousand stock options and 1.3 million warrants to purchase common shares outstanding.

In these consolidated financial statements, all references to number of shares, stock options and warrants in the current and past periods have been adjusted to reflect the impact of the consolidation. All amounts based on the number of shares, stock options or warrants, unless otherwise specified, such as earnings (loss) per share and weighted average issuance price in the case of stock options have been adjusted to reflect the impact of 1-for-30 share consolidation.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

2.	Changes in accounting policies:

(a)

Goodwill and intangible assets:

Effective June 1, 2009, the Company adopted The Canadian Institute of Chartered Accountants' ("CICA") Handbook Section 3064, Goodwill and Intangible Assets, which replaced Handbook Section 3062, Goodwill and Other Intangible Assets ("Section 3062"), and Section 3450, Research and Development Costs and establishes the standards for the recognition, measurement, presentation and disclosure of goodwill and intangible assets. The adoption of this new standard did not have an impact on the Company's consolidated financial statements.

(b)

Financial instruments:

Effective June 1, 2009, the Company adopted the amendments under Handbook Section 3862, Financial Instruments - Disclosures ("Section 3862"), to include additional disclosure requirements about fair value measurement for financial instruments and liquidity risk disclosures. These amendments require a three level hierarchy that reflects the significance of the inputs used in making the fair value measurements. Fair value of assets and liabilities included in Level 1 are determined by reference to quoted prices in active markets for identical assets and liabilities. Assets and liabilities in Level 2 include valuations using inputs other than the quoted prices for which all significant inputs are based on observable market data, either directly or indirectly. Level 3 valuations are based on inputs that are not based on observable market data. The adoption of the new standard did not have a material impact on the consolidated financial statements.

(c)

Credit risk and fair value of financial assets and financial liabilities:

Effective January 1, 2009, the Company adopted Emerging Issue Committee Abstract 173 ("EIC 173"), Credit Risk and the Fair Value of Financial Assets and Financial Liabilities. EIC 173 requires the Company to take into account the Company's own credit risk and the credit risk of the counterparty in determining the fair value of financial assets and financial liabilities, including derivative instruments. The adoption of the new standard did not have a material impact on the consolidated financial statements.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies:

(a)

Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its 80% owned subsidiary, NuChem Pharmaceuticals Inc. ("NuChem"). On May 31, 2009, its wholly owned subsidiary, GeneSense Technologies Inc. ("GeneSense") was wound up and its operations and net assets assumed by Lorus Therapeutics, the parent company. On June 19, 2009 the Company disposed of its shares of Pharma Immune Inc. ("Pharma Immune") (note 13). The results of operations for acquisitions are included in these consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated on consolidation.

The consolidated financial statements have been prepared by management in accordance with Canadian GAAP.

(b)

Revenue recognition:

Revenue includes product sales, service, license and royalty revenue.

The Company recognizes revenue from product sales and provision of services when persuasive evidence of an arrangement exists, delivery has occurred, the Company's price to the customer is fixed or determinable and collectability is reasonably assured. The Company allows customers to return product. Provisions for these returns are estimated based on historical return and exchange levels, and third-party data with respect to inventory levels in the Company's distribution channels.

Revenue from multiple element arrangements consisting of non-refundable license fees, receipt of milestone payments, royalty and delivery of services over a defined term are recognized in accordance with Emerging Issues Committee Abstract No. 142, Revenue Arrangements with Multiple Deliverables. The Company recognizes the non-refundable license fee as revenue when the technology license is delivered, the fee is fixed or determinable, collection of the amount was probable and there is no continuing involvement or obligation to perform under the arrangement. Any milestone payment subsequently received from the customer is recognized when the customer acknowledges achievement of the milestone, when the fee is fixed or determinable and collection of the amount is probable. If the multiple deliverables in an arrangement do not meet the criteria for separation, the proceeds from the entire arrangement are deferred and recognized as revenue on a proportionate performance basis, or over the term of the arrangement.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

(c)

Financial instruments:

Financial instrument classification:

Management determines the classification of financial assets and financial liabilities at initial recognition and, except in very limited circumstances, the classification is not changed subsequent to initial recognition. The classification depends on the purpose for which the financial instruments were acquired, their characteristics and/or management's intent. Transaction costs with respect to instruments not classified as held-for-trading are recognized as an adjustment to the cost of the underlying instruments and amortized using the effective interest method.

The Company's financial instruments were classified in the following categories:

(i)

Cash and cash equivalents:

Cash and cash equivalents are classified as held-for-trading investments and measured at fair value. By virtue of the nature of these assets, fair value is generally equal to cost plus accrued interest. Where applicable, any significant change in market value would result in a gain or loss being recognized in the consolidated statements of operations and comprehensive income. As a result of adopting the new standards, there was no material change in valuation of these assets.

The Company considers unrestricted cash on hand and in banks, term deposits and guaranteed investment certificates with original maturities of three months or less as cash and cash equivalents.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

(ii)

Short-term investments:

Short-term investments are liquid Canadian government or corporate instruments having original maturity dates greater than three months and less than one year and are classified as held-to-maturity investments, except where the Company does not intend to, or cannot reasonably expect to hold the investment to maturity in which case the investment is designated as held-for-trading. Held-to-maturity investments are measured at amortized cost using the effective interest rate method, while held-for-trading investments are measured at fair value and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive income.

Upon adoption of CICA Handbook Section 3855, Financial Instruments - Recognition and Measurement ("Section 3855"), on June 1, 2007, the Company designated certain corporate instruments then having maturities greater than one year previously carried at amortized cost as held-for-trading investments. This change in accounting policy resulted in a decrease in the carrying amount of these investments of $27 thousand and a corresponding increase in the opening deficit at June 1, 2007. The Company recognized a net unrealized gain in the consolidated statements of operations and comprehensive income for the year ended May 31, 2010 of $8 thousand (2009 - $10 thousand, 2008 - $7 thousand).

The Company invests in high-quality fixed income government and corporate investments with low credit risk.

(iii)

Accounts payable and accrued liabilities:

Accounts payable and accrued liabilities and promissory note payable are typically short-term in nature and classified as other financial liabilities. These liabilities are carried at amortized cost.

(iv)

Secured convertible debentures:

The secured convertible debentures, prior to their repurchase in June 2009, were classified as other financial liabilities and accounted for at amortized cost using the effective interest method. The deferred financing charges related to the secured convertible debentures for the periods presented were included as part of the carrying value of the secured convertible debentures and were amortized using the effective interest method.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

(v)

Embedded derivatives:

Where applicable, the Company separates embedded derivatives from a related host contract and measures those embedded derivatives at fair value. Subsequent changes in fair value of embedded derivatives are recognized in the consolidated statements of operations and comprehensive income in the period in which the change occurs. In the periods, presented, the Company did not identify any embedded derivatives that require separation from the related host contract.

(vi)

Transaction costs:

Transaction costs directly attributable to the acquisition or issuance of financial assets or liabilities are accounted for as part of the respective asset or liability's carrying value at inception except for held-for-trading securities where the costs are expensed immediately.

(vii)

Fair value hierarchy:

All financial instruments are required to be measured at fair value on initial recognition, except for certain related party transactions. Financial instruments are required to be measured at fair value at each reporting. Financial instruments have been ranked using a three-level hierarchy that reflects the significance of the inputs used in making the fair value measurements:

•

Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

•

Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

•

Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

See note 15 for a breakdown of these financial instruments.

(d)

Fixed assets:

Fixed assets are recorded at cost less accumulated depreciation and amortization. The Company records depreciation and amortization at rates that charge operations with the cost of the assets over their estimated useful lives on a straight-line basis as follows:



Furniture and equipment	Over 3 to 5 years

(e)

Research and development:

Research costs are charged to expense as incurred. Development costs, including the cost of drugs for use in clinical trials, are expensed as incurred unless they meet the criteria under Canadian GAAP for deferral and amortization. No development costs have been deferred to date.

(f)

Goodwill:

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets acquired in the GeneSense business combination. Goodwill acquired in a business combination is tested for impairment on an annual basis and at any other time if an event occurs or circumstances change that would indicate that impairment may exist. The impairment test is carried out in two steps.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

In the first step, the carrying amount of the reporting unit including goodwill is compared with its fair value. When the fair value of a reporting unit including goodwill exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired and the second step of the impairment test is unnecessary.

The second step is carried out when the carrying amount of a reporting unit exceeds its fair value, in which case the implied fair value of the reporting unit's goodwill is compared with its carrying amount to measure the amount of the impairment loss if any. The implied fair value of goodwill is determined in the same manner as the value of goodwill is determined in a business combination.

The Company has identified no impairment relating to goodwill for 2010, 2009 and 2008.

(g)

Acquired patents and licenses:

Intangible assets with finite lives acquired in a business combination or other transaction are amortized over their estimated useful lives.

The Company capitalized the cost of acquired patent and license assets on the acquisitions of GeneSense and the NuChem compounds. The nature of this asset is such that it was categorized as an intangible asset with a finite life. These assets have now been fully amortized.

(h)

Impairment of long-lived assets:

The Company reviews long-lived assets which include fixed assets and intangible assets with finite useful lives for impairment annually or more frequently if events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. If the sum of the undiscounted expected future cash flows expected to result from the use and eventual disposition of an asset is less than its carrying amount, it is considered to be impaired. An impairment loss is measured at the amount by which the carrying amount of the asset exceeds its fair value, which is estimated as the expected future cash flows discounted at a rate proportionate with the risks associated with the recovery of the asset.

The Company has identified no impairment relating to long-lived assets for 2010, 2009 and 2008.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

(i)

Stock-based compensation:

The Company has a stock-based compensation plan (the "Plan") available to officers, directors, employees and consultants with grants under the Plan approved by the Company's Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the Company's stock on the day prior to the grant. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no greater than 10 years from the date of grant.

The Company uses the fair value based method of accounting for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black Scholes Option Pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options. Actual forfeitures are accounted for as they occur.

Stock options awarded to non-employees are accounted for using the fair value method and expensed as the service or product is received. The Company calculates the fair value of each stock option grant using the Black Scholes Option Pricing model at the grant date. Consideration paid on the exercise of stock options and warrants is credited to common shares.

The Company has a deferred share unit plan that provides directors the option of receiving payment for their services in the form of share units rather than common shares or cash. Share units entitle the director to elect to receive, on termination of his or her services with the Company, an equivalent number of common shares, or the cash equivalent of the market value of the common shares at that future date. For units issued under this plan, the Company records an expense and a liability equal to the market value of the shares issued. The accumulated liability is adjusted for market fluctuations on a quarterly basis. There are currently no units issued under this plan.

The Company has an alternate compensation plan ("2009 ACP") that provides directors and senior management ("participants") with the option of receiving director's fees, salary, bonuses or other remuneration ("Remuneration") in common shares rather than cash. Under the plan, the participant receives an allotment from treasury of such number of shares as will be equivalent to the cash value of the Remuneration determined by dividing the Remuneration by the weighted average closing common share price for the five trading days prior to payment date (the "5-day VWAP"). The issue price of the shares is the 5-day VWAP. There are currently no shares allotted for issuance under this plan.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

(j)

Investment tax credits:

The Company is entitled to Canadian federal and provincial investment tax credits, which are earned as a percentage of eligible research and development expenditures incurred in each taxation year. Investment tax credits are accounted for as a reduction of the related expenditure for items of a current nature and a reduction of the related asset cost for items of a long-term nature, provided that the Company has reasonable assurance that the tax credits will be realized. Investment tax credits receivable at May 31, 2010 of $400 thousand are classified as prepaid expenses and other assets (2009 - $600 thousand).

(k)

Income taxes:

Income taxes are accounted for using the asset and liability method. Under this method, future tax assets and liabilities are recorded for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, and operating loss and research and development expenditure carryforwards. Future tax assets and liabilities are measured using enacted or substantively enacted tax rates expected to apply when the asset is realized or the liability is settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the year that enactment or substantive enactment occurs. A valuation allowance is recorded if it is not more likely than not that some portion of or all of a future tax asset will be realized.

(l)

Earnings (loss) per share:

Basic earnings (loss) per common share is calculated by dividing the earnings (loss) for the year by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per common share is calculated by dividing the loss for the year by the sum of the weighted average number of common shares outstanding and the dilutive common equivalent shares outstanding during the year. Common equivalent shares consist of the shares issuable upon exercise of stock options and warrants as applicable, calculated using the treasury stock method. Common equivalent shares are not included in the calculation of the weighted average number of shares outstanding for diluted loss per common share when the effect would be anti-dilutive.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

(m)

Segmented information:

The Company is organized and operates as one operating segment, the research and development of anti-cancer therapies. Substantially all of the Company's identifiable assets as at May 31, 2010 and 2009 are located in Canada.

(n)

Foreign currency translation:

Foreign currency transactions are translated into Canadian dollars at rates prevailing on the transaction dates. Monetary assets and liabilities are translated into Canadian dollars at the rates in effect on the balance sheets dates. Gains or losses resulting from these transactions are accounted for in the loss for the period and are not significant.

(o)

Use of estimates:

The preparation of financial statements in accordance with Canadian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates and assumptions. Significant areas requiring the use of management estimates include the historical valuation of the convertible debentures, fair value of guarantees, fair value of the obligation for indemnifications provided on the Arrangement between the Company and Old Lorus, the fair value of long-lived assets and the determination of impairment thereon, the economic lives of intangible assets, the recoverability of future income tax assets, the determination of fair values of financial instruments, as well as the determination of stock-based compensation and the fair value of warrants issued.

(p)

Recent Canadian accounting pronouncements not yet adopted:

The Canadian Accounting Standards Board ("AcSB") requires all Canadian publicly accountable entities to adopt International Financial Reporting Standards ("IFRS") for years beginning on or after January 1, 2011. The Company's first annual filing under IFRS will be for the year ended May 31, 2012; its first quarterly filing under IFRS will be for the quarter ending August 31, 2011 and will include IFRS comparative figures for the period ended August 31, 2010. Accordingly, the Company's adoption date for IFRS is June 1, 2011, but its transition date ("Transition Date") is June 1, 2010 in order to present IFRS comparative figures in the Company's 2011 consolidated financial statements.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

3.	Significant accounting policies (continued):

IFRS uses a conceptual framework similar to Canadian GAAP, however, there are significant differences in recognition, measurement and disclosure. Given the nature of Lorus' business and the make-up of its current balance sheets, IFRS could have an impact on its reported financial statements. The Company's implementation of IFRS will require the Company to make and disclose certain policy choices and increase the amount of disclosure necessary to fulfill its IFRS reporting obligations.

During 2009, a detailed project plan with expected milestones was established and approved by senior management of the Company. There are three phases to the plan: a diagnostic phase, a solution development phase and an implementation phase. The plan involves an assessment of the impact of the move to IFRS on accounting and reporting (including any Impact on the Company's internal controls over financial reporting, disclosure controls and procedures, IT systems and processes, and the business implications of this conversion). The Company has allocated resources and included in its project plan training required for both the conversion team and all impacted employees of the organization.

The Company has substantially completed the diagnostic phase and has begun the second and third phases of its plan. During 2010, the Company continued to make progress on its established milestones including analyzing its policy selections both on conversion and post conversion as well as evaluating new financial statement disclosure requirements.

Moving forward, the Company expects to meet all milestones leading up to the conversion in 2012. In 2011, the Company expects to finalize the elections under IFRS 1, publish new policy choices and quantify the impact of the changes to the consolidated financial statements in preparation for the 2012 conversion.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

4.	Short-term investments, marketable securities and other investments:


	Less than			Greater than
	one year			one year					Yield to
2010	maturities			maturities			Total		maturity

Corporate investments (guaranteed investment certificates)		$	247		$	-	$	247		-


	Less than			Greater than
	one year			one year					Yield to
2009	maturities			maturities			Total		maturity

Corporate investments (guaranteed investment certificates)		$	248		$	242	$	490		-

Certain corporate investments, totalling $247 thousand at May 31, 2010 (2009 - $490 thousand), have been designated as held-for-trading investments, and have been classified as short-term investments on the consolidated balance sheets. These investments are carried at fair value. The net increase in fair value for the year ended May 31, 2010 amounted to $8 thousand (2009 - $10 thousand) and has been included in the consolidated statements of operations and comprehensive income in interest income.

5.	Fixed assets:


			Accumulated
			depreciation
			and			Net book
2010	Cost		amortization			value

Furniture and equipment	$	2,907		$	2,760		$	147

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

5.	Fixed assets (continued):


			Accumulated
			depreciation
			and			Net book
2009	Cost		amortization				value

Furniture and equipment	$	2,905		$	2,674		$	231

6.	Share capital:

(a)

Continuity of common shares and warrants:


	Common shares					Warrants
	Number		Amount			Number		Amount
(in thousands)					(in thousands)

Balance, May 31, 2007		7,076	$	157,714			-	$	-
Interest payments (note 13)		179		1,029			-		-

Balance, May 31, 2008		7,255		158,743			-		-
Interest payments (note 13)		354		707			-		-
Issuance of units (b)		951		2,790			571		417

Balance, May 31, 2009		8,560		162,240			571		417
Interest payments (note 13)		7		15			-		-
Issuance of units (b)		1,366		1,665			755		622

Balance, May 31, 2010		9,933	$	163,920			1,326	$	1,039

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

6.	Share capital (continued):

(b)

Share issuances:

On November 27, 2009, pursuant to a private placement, the Company issued 1.366 million common shares and 683 thousand common share purchase warrants in exchange for cash consideration of $2.5 million. This amount includes the principal amount of $1.0 million originally received by way of a loan from a director on October 6, 2009 which was applied to subscribe for units of the Company ("Units") as part of the private placement. In addition, the Company issued 72 thousand brokers' warrants to purchase an equivalent number of common shares at $2.40 until May 27, 2011. The total costs associated with the transaction were approximately $250 thousand which included the $77 thousand which represented the fair value of the brokers' warrants. The Company has allocated the net proceeds of the private placement to the common shares and the common share purchase warrants based on their relative fair values. Based on relative fair values, $1.7 million of the net proceeds was allocated to the common shares and $545 thousand to the common share purchase warrants.

On June 25, 2008, the Company filed a short-form prospectus for a rights offering to its shareholders. Under the rights offering, holders of the Company's common shares as of July 9, 2008 (the "Record Date") received one right for each common share held as of the Record Date. Each four rights entitled the holder thereof to purchase a Unit. Each Unit consists of one common share of the Company at $3.90 and a one-half common share purchase warrant to purchase additional common shares of the Company at $4.53 until August 7, 2010. All unexercised rights expired on August 7, 2008. Pursuant to the rights offering, the Company issued 951 thousand common shares and 571 thousand common share purchase warrants in exchange for cash consideration of $3.7 million. The total costs associated with the transaction were approximately $500 thousand. The Company has allocated the net proceeds of $3.2 million received from the issuance of the Units to the common shares and the common share purchase warrants based on their relative fair values. The fair value of the common share purchase warrants has been determined based on an option-pricing model. The resulting allocation based on relative fair values resulted in the allocation of $2.8 million to the common shares and $417 thousand to the common share purchase warrants.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

6.	Share capital (continued):

On July 10, 2007, as part of the Arrangement described in note 1(b), the Company surrendered its original common share issued when the Company was incorporated, ("Original Share"), and exchanged all of the shares in Old Lorus for an equivalent number of shares of the Company.

(c)

Terminated U.S. financing:

In April 2010, the Company filed a Registration Statement on Form F-1 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") for an offering of up to US$17.5 million of units in the United States.

In August 2010, subsequent to year end, the Company announced that due to unfavourable market conditions the Registration Statement would be withdrawn and the public financing would not proceed.

The Company incurred fees of approximately $569 thousand related to this filing which have been included in general and administrative expenses for the year ended May 31, 2010 and an additional $200 thousand in fees incurred subsequent to year end which will be paid in the year ended May 31, 2011.

(d)

Contributed surplus:


	2010		2009		2008

Balance, beginning of year	$	10,744	$	9,181	$	8,525
Forfeiture of stock options		317		1,563		656
Equity portion of secured convertible
Debenture (note 13)		3,814		-		-

Balance, end of year	$	14,875	$	10,744	$	9,181

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

6.	Share capital (continued):

(e)

Continuity of stock options:


	2010			2009			2008

Balance, beginning of the year	$	3,845		$	4,961		$	4,898
Stock option expense		176			446			719
Forfeiture of stock options		(317	)		(1,562	)		(656	)

Balance, end of year	$	3,704		$	3,845		$	4,961

(f)

Alternate compensation plans:

The Company did not issue any share units under its deferred share unit plan or allot any shares for issuance under its 2009 ACP.

(g)

Employee share purchase plan:

The Company' has an employee share purchase plan ("ESPP"). The purpose of the ESPP is to assist the Company in retaining the services of its employees, to secure and retain the services of new employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. The ESPP provides a means by which employees of the Company and its affiliates may purchase common shares of the Company at a discount through accumulated payroll deductions with each offering having a three month duration. Participants may authorize payroll deductions of up to 15% of their base compensation for the purchase of common shares under the ESPP. For the year ended May 31, 2010, 3,159 (2009 - 7,966; 2008 - 9,400) common shares have been purchased under the ESPP, and the Company has recognized an expense of $2 thousand (2009 - $3 thousand; 2008 - $10 thousand) related to this plan in these consolidated financial statements.

(h)

Earnings/loss per share:

For the year ended May 31, 2010, the determination of diluted earnings per share includes in the calculation all common shares potentially issuable upon the exercise of stock options and share purchase warrants, using the treasury stock method.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

6.	Share capital (continued):

Diluted earnings per share, using the treasury stock method, assumes outstanding stock options and share purchase warrants are exercised at the beginning of the period, and the Company's common shares are purchased at the average market price during the period from the funds derived on the exercise of these outstanding options and share purchase warrants. Stock options and share purchase warrants with a strike price above the average market price for the period were excluded from the calculation of fully diluted earnings per share as to include them would have increased the earnings per share.

7.	Stock-based compensation:

Stock option plan:

Under the Company's stock option plan, options may be granted to directors, officers, employees and consultants of the Company to purchase up to a maximum of 15% of the total number of outstanding common shares, currently estimated at 1,490,000 options. Options are granted at the fair market value of the common shares on the date immediately preceding the date of the grant. Options vest at various rates (immediate to three years) and have a term of 10 years. Stock option transactions for the three years ended May 31, 2010 are summarized as follows:


	2010					2009					2008
				Weighted					Weighted					Weighted
				average					average					average
				exercise					exercise					exercise
	Options			price		Options			price		Options			price

Outstanding, beginning of year		562,358		$	8.66		547,874		$	13.52		432,830		$	17.69
Granted		189,406			2.41		170,807			3.39		201,637			6.26
Exercised		-			-		-			-		-			-
Forfeited		(78,863	)		11.24		(156,323	)		19.94		(86,593	)		17.44

Outstanding, end of year		672,901			6.60		562,358			8.66		547,874			13.52

Exercisable, end of year		439,452		$	8.54		323,555		$	11.39		341,296		$	14.91

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

7.	Stock-based compensation (continued):

The following table summarizes information about stock options outstanding at May 31, 2010:


	Options outstanding						Options exercisable
			Weighted
			average		Weighted				Weighted
			remaining		average				average
Range of			contractual		exercise				exercise
exercise prices	Options		life (years)		price		Options		price
$2.10 - $7.49		484,152		8.31	$	3.81		250,703	$	4.64
$7.50 - $14.99		146,955		5.39		8.88		146,955		8.88
$15.00 - $29.99		28,852		3.88		24.62		28,852		24.62
$30.00 - $75.00		12,942		2.08		44.38		12,942		44.38
		672,901		7.36		6.60		439,452		8.54

For the year ended May 31, 2010, stock option expense comprised $83 thousand (2009 - $127 thousand; 2008 - $171 thousand) related to research and development and $93 thousand (2009 - $319 thousand; 2008 - $548 thousand) related to general and administrative.

The following assumptions were used in the Black-Scholes option pricing model to determine the fair value of stock options granted during the year:


	2010			2009			2008

Risk-free interest rate		2.44% - 2.60	%		2.00% - 3.50	%		3.75% - 4.70	%
Expected volatility		82% - 124	%		76	%		77% - 80	%
Expected dividend yield		-			-			-
Expected life of options	5 years			5 years			5 years
Weighted average fair value of options granted or modified during the year	$	1.43		$	2.16		$	4.05

The Company has assumed no forfeiture rate as adjustments for actual forfeitures are made in the year they occur.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

8.	Capital risk management:

The Company's objectives when managing capital are to:

(a)

maintain its ability to continue as a going concern in order to provide returns to shareholders and benefits to other stakeholders;

(b)

maintain a flexible capital structure which optimizes the cost of capital at acceptable risk; and

(c)

ensure sufficient cash resources to fund its research and development activity, to pursue partnership and collaboration opportunities and to maintain ongoing operations.

At May 31, 2010, the capital structure of the Company consisted of equity comprised of share capital, warrants, stock options, contributed surplus and deficit. The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share issuances, acquiring or disposing of assets, adjusting the amount of cash and short-term investments balances or by undertaking other activities as deemed appropriate under the specific circumstances. The Company has forecasted that its current capital resources will not be sufficient to carry its research and development plans and operations for the next twelve months (note 1(a)) without additional financing.

The Company is not subject to externally imposed capital requirements and the Company's overall strategy with respect to capital risk management remains unchanged from the year ended May 31, 2009.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

9.	Financial instruments and risk management:

(a)

Financial instruments:

The Company has classified its financial instruments as follows:


	2010		2009

Financial assets:
Cash and cash equivalents, consisting of term deposits and guaranteed investment certificates at fair value	$	667	$	5,374

Short-term investments, held-for-trading, recorded at fair value		247		490

Financial liabilities:
Accounts payable, measured at amortized cost		387		299
Accrued liabilities, measured at amortized cost		1,458		1,131
Secured convertible debentures, measured at amortized cost		-		14,448
Promissory note payable, measured at amortized cost		1,000		-

(b)

Financial risk management:

The Company has exposure to credit risk, liquidity risk and market risk. The Company's Board of Directors has the overall responsibility for the oversight of these risks and reviews the Company's policies on an ongoing basis to ensure that these risks are appropriately managed.

(i)

Credit risk:

Credit risk is the risk of financial loss to the Company if a customer, partner or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's cash and cash equivalents and short-term investments. The carrying amount of the financial assets represents the maximum credit exposure.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

9.	Financial instruments and risk management (continued):

The Company manages credit risk for its cash and cash equivalents and short-term investments by maintaining minimum standards of R1 low or A low investments and the Company invests only in highly rated Canadian corporations with debt securities that are traded on active markets and are capable of prompt liquidation.

(ii)

Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, the Board considers securing additional funds through equity, debt or partnering transactions. The Company manages its liquidity risk by continuously monitoring forecasts and actual cash flows. Refer to note 1(a) for further discussion on the Company's ability to continue as a going concern.

(iii)

Market risk:

Market risk is the risk that changes in market prices, such as interest rates, foreign exchange rates and equity prices will affect the Company's income or the value of its financial instruments.

The Company is subject to interest rate risk on its cash and cash equivalents and short-term investments. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to interest rates on the investments, owing to the relative short-term nature of the investments. The Company does not have any material interest bearing liabilities subject to interest rate fluctuations.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

9.	Financial instruments and risk management (continued):

Financial instruments potentially exposing the Company to foreign exchange risk consist principally of accounts payable and accrued liabilities. The Company holds minimal amounts of U.S. dollar denominated cash, purchasing on an as needed basis to cover U.S. dollar denominated payments. At May 31, 2010, U.S. dollar denominated accounts payable and accrued liabilities amounted to $270 thousand (2009 - $70 thousand). Assuming all other variables remain constant, a 10% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an increase or decrease in loss for the year and comprehensive loss of $27 thousand (2009 - $7 thousand). The Company does not have any forward exchange contracts to hedge this risk.

The Company does not invest in equity instruments of other corporations.

10.	Income taxes:

Income tax recoveries attributable to losses from operations differ from the amounts computed by applying the combined Canadian federal and provincial income tax rates to pre-tax income from operations primarily as a result of the provision of a valuation allowance on net future income tax benefits.

Significant components of the Company's future tax assets are as follows:


	2010			2009

Non-capital loss carryforwards	$	2,197		$	3,099
Capital loss carryforwards		-			218
Research and development expenditures		4,237			4,518
Book over tax depreciation		529			749
Intangible asset		3,115			3,386
Ontario harmonization tax credit		347			179
Other		172			-

Future tax assets		10,597			12,149

Valuation allowance		(10,597	)		(12,149	)

	$	-		$	-

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

10.	Income taxes (continued):

During the year ended May 31, 2010, the Company reached a settlement with the convertible debenture holders (note 13) which resulted in an accounting gain of $11.0 million. For tax purposes this transaction resulted in a taxable capital gain of $5.7 million. There are no taxes payable on this gain as the Company has sufficient capital and non-capital losses to offset the gain.

During the year ended May 31, 2008, under the Arrangement, numerous steps were undertaken as part of a taxable reorganization. However, these steps did not result in any taxes payable as the tax benefit of income tax attributes was applied to eliminate any taxes otherwise payable. Of the total unrecognized future tax assets available at the time of the Arrangement, approximately $7.0 million was transferred to the Company and the balance remained with Old Lorus and is subject to the indemnification agreement (note 1(b)). Those tax attributes remaining with Old Lorus are no longer available to the Company.

In assessing the realizable benefit from future tax assets, management considers whether it is more likely than not that some portion or all of the future tax assets will not be realized. The ultimate realization of future tax assets is dependent on the generation of future taxable income during the years in which those temporary differences become deductible. Management considers projected future taxable income, uncertainties related to the industry in which the Company operates and tax planning strategies in making this assessment. Due to the Company's stage of development and operations, and uncertainties related to the industry in which the Company operates, the tax benefit of the above amounts has been completely offset by a valuation allowance.

The Company has undeducted research and development expenditures, totalling $16.9 million that can be carried forward indefinitely. In addition, the Company has non-capital loss carryforwards of $8.8 million. To the extent that the non-capital loss carryforwards are not used, they expire as follows:


2015	$	10
2026		11
2027		4
2028		4,359
2029		4,387
2030		16

	$	8,787

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

10.	Income taxes (continued):

Income tax rate reconciliation:


	2010			2009			2008

Income tax expense (recovery) based on statutory rate of 32.6% (2009 - 33.3%, 2008 - 35.0%)	$	1,738		$	(2,950	)	$	(2,217	)
Expiry of losses		46			247			127
Change in valuation allowance		(1,552	)		3,068			2,048
Non deductible accretion, stock-based compensation and capital gains		(1,694	)		582			(1,880	)
Ontario harmonization tax credit		-			(260	)		-
Change in substantively enacted tax rates		1,643			299			1,585
Adjustment of prior year research and development expenditures		-			(856	)		-
Other		(181	)		(130	)		337

	$	-		$	-		$	-

11.	Research and development programs:

The Company has product candidates in three classes of anticancer therapies:

•

RNA-targeted (antisense and siRNA) therapies, based on synthetic segments of DNA or RNA designed to bind to the messenger RNA that is responsible for the production of proteins over-expressed in cancer cells;

•

small molecule therapies based on anti-angiogenic, anti-proliferative and anti-metastatic agents; and

•

immunotherapy, based on macrophage-stimulating biological response modifiers.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

11.	Research and development programs (continued):

(a)

RNA-Targeted Therapies:

The Company's RNA-targeted drug candidates include LOR-2040 and LOR-1284. The Company has reported Phase II clinical results, completed to the end-of-stage assessment time point, of LOR-2040 in combination with cytarabine in relapsed and refractory acute myeloid leukemia ("AML") patient population. Based on these data, the Company is proceeding with protocol development for the expanded development program. LOR-1284 is in pre-clinical stage of development.

(b)

Small Molecule Program:

The Company has small molecule drug screening technologies and preclinical scientific expertise, which it is using to create a drug candidate pipeline. The Company's proprietary group of small molecule compounds includes lead drug LOR-253.

(c)

Immunotherapy:

The Company's immunotherapy product candidates are Virulizin® and Interleukin-17E ("IL-17E"). In June 2009, as part of the consideration for our repurchase of the secured convertible debentures from The Erin Mills Investment Corporation ("TEMIC"), the Company assigned to TEMIC its rights under the license agreement with Zor Pharmaceuticals, LLC ("ZOR"), and sold to TEMIC its intellectual property rights associated with Virulizin®. In return, the Company will be entitled to 50% of the deal value of any transaction completed in ZOR and non-ZOR territories. IL-17E is a protein-based therapeutic that the Company is developing as an immunotherapy for cancer treatment.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

11.	Research and development programs (continued):


							Period from
							inception on
							September 5,
							1986 to
	Years ended May 31,						May 31,
	2010		2009		2008		2010

RNA-Targeted Therapies:
Expensed	$	945	$	1,123	$	3,291	$	36,904
Acquired		-		-		-		11,000
Small molecules:
Expensed		1,572		2,634		2,821		14,413
Acquired		-		-		-		1,228
Immunotherapy:
Expensed		-		-		148		75,197

Total expensed	$	2,517	$	3,757	$	6,260	$	126,514

Total acquired	$	-	$	-	$	-	$	12,228

Amortization of the acquired patents and licenses is included in the expensed line of the table.

12.	Supplemental cash flow and other information:

Cash and cash equivalents consist of:


	2010		2009

Cash	$	667	$	2,676
Term deposits and guaranteed investment certificates		-		2,698

	$	667	$	5,374

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

12.	Supplemental cash flow and other information (continued):

Change in non-cash operating working capital is summarized as follows:


									Period from
									inception on
									September 5,
									1986 to
	Years ended May 31,								May 31,
	2010		2009			2008				2010

Prepaid expenses and other assets	$	190	$	(105	)	$	(386	)		$	(60	)
Accounts payable		88		(624	)		(181	)			(857	)
Accrued liabilities		377		(213	)		(227	)			1,118
Promissory note payable		1,000		-			-				1,000

	$	1,655	$	(942	)	$	(794	)		$	1,201

During the year ended May 31, 2010, the Company received interest of $139 thousand (2009 -$367 thousand; 2008 - $519 thousand).

During the year ended May 31, 2010, the Company paid $27 thousand (2009 - nil; 2008 - nil) in cash interest related to the convertible debentures settled on June 22, 2009.

During the year ended May 31, 2010, the Company paid nil (2009 - nil; 2008 - nil) in income taxes and received nil (2009 - nil; 2008 - nil) in income taxes.

13.	Convertible debentures:

On October 6, 2004, the Company entered into a Subscription Agreement (the "Agreement") to issue an aggregate of $15.0 million of secured convertible debentures (the "debentures") to TEMIC (the "debenture holder"). The debentures were secured by a first charge over all of the assets of the Company.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

13.	Convertible debentures (continued):

The Company received three tranches of $5.0 million on each of October 6, 2004, January 14 and April 15, 2005. All debentures issued under the Agreement were due on October 6, 2009 and subject to interest payable monthly at a rate of prime plus 1%. Interest was payable in common shares of the Company. Common shares issued in payment of interest were issued at a price equal to the weighted average trading price of such shares for the 10 trading days immediately preceding their issue in respect of each interest payment. For the year ended May 31, 2010, the Company issued 7,000 (2009 - 354,000; 2008 - 179,433) shares in settlement of approximately $15 thousand (2009 - $707 thousand; 2008 - $1.0 million) in interest. In addition the Company paid $12 thousand of interest expense in cash.

With the issuance of each $5.0 million debenture, the Company issued to the debenture holder from escrow 33,333 purchase warrants expiring October 6, 2009 to buy common shares of the Company at a price per share equal to $30.00. In July 2007, the 100,000 common share purchase warrants were repurchased in connection with the Arrangement (note 1(b)).

The debentures contained both a liability and an equity element, represented by the conversion option and, therefore, under Canadian GAAP, these two elements were split and classified separately as debt and equity. In addition, as noted above, the debenture holder received 33,333 purchase warrants on the issuance of each tranche of convertible debt (warrants were repurchased in July 2007). The Company allocated the total proceeds received from the issuance of the debentures to these three elements based on their relative fair values. The fair value of the purchase warrants was determined based on an option pricing model. The fair value of the debt was based on the discounted cash flows using an estimated cost of borrowing of 15% to represent an estimate of what the Company may have borrowed as secured debt without a conversion option or purchase warrant. The debentures conversion option was valued using a trinomial model. The resulting allocation based on relative fair values resulted in the allocation of $9.8 million to the debt instrument, $4.1 million to the conversion option and $1.1 million to the purchase warrants. The financing fees totalling $1.1 million related to the issuance of the convertible debentures were allocated pro rata between deferred financing charges of $652 thousand, against the equity portion of the convertible debentures of $322 thousand and against the purchase warrants of $87 thousand. This allocation resulted in net amounts allocated to the equity portion of the debentures and warrants of $3.8 million and $991 thousand, respectively.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

13.	Convertible debentures (continued):

Prior to the adoption of Section 3855 on June 1, 2007, deferred financing costs were amortized over the five-year life of the Agreement. As a consequence of the adoption of Section 3855, deferred financing costs at June 1, 2007 were reclassified and reduced the carrying value of the debentures. Deferred financing costs were recognized in the consolidated statements of operations as accretion expense.

Each reporting period, the Company was required to accrete the carrying value of the convertible debentures such that at maturity on October 6, 2009, the carrying value of the debentures will be their face value of $15.0 million. For the year ended May 31, 2010, the Company has recognized $80 thousand (2009 - $1.7 million; 2008 - $1.2 million) in accretion expense.

On June 22, 2009, the Company reached a settlement with TEMIC with respect to the purchase and settlement of the $15.0 million secured convertible debentures.

Under the Agreement, the Company purchased all of the convertible debentures from TEMIC for consideration that included a cash payment on close of the transaction of $3.3 million, the assignment of the rights under the license agreement with ZOR certain intellectual property associated with Virulizin® and all of the Company's shares in its wholly owned subsidiary, Pharma Immune, which held an equity interest in ZOR (the "Consideration"). Under the agreement, the Company is entitled to 50% of any royalties received under the ZOR license agreement and 50% of the value of any transaction completed in territories not covered by the ZOR license agreement. The Company also retains a perpetual royalty free license for the animal use of Virulizin®. TEMIC will be fully responsible for all clinical and regulatory costs associated with the commercialization of Virulizin® in territories not covered by the ZOR license agreement. The Company will assist TEMIC with certain agreed upon services.

For receipt of the Consideration, TEMIC has released all security interest in the assets of the Company.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

13.	Convertible debentures (continued):

As a result of the transaction, the Company recognized a gain on the repurchase of the debentures of $11.0 million reflecting the difference between the fair value of the debentures at the repurchase date, net of transaction costs of approximately $221 thousand, and the cash payment amount of $3.3 million. In addition, as a result of extinguishing the debentures in the amount of $3.8 million, the equity portion of the debentures, was transferred to contribute surplus. The gain on repurchase of the debentures did not result in income taxes payable as the Company has sufficient capital loss and non-capital loss carryforwards to shelter these gains. Capital loss and non-capital loss carryforwards, and the associated valuation allowance have been reduced accordingly.

14.	Contingencies, commitments and guarantees:

(a)

Operating lease commitments:

The Company has entered into operating leases for premises and equipment under which it is obligated to make minimum annual payments of approximately $129 thousand in 2011, $9 thousand in 2012. The Company's current facility lease expires in March 2011.

During the year ended May 31, 2010, operating lease expenses were $146 thousand (2009 - $143 thousand; 2008 - $140 thousand).

(b)

Other contractual commitments:

In December 1997, the Company acquired certain patent rights and a sub-license to develop and commercialize the anticancer application of certain compounds in exchange for a 20% share interest in NuChem; a payment of US$350 thousand in shares of the Company; and up to US$3.5 million in cash.

To date, the Company has made cash payments of US$500 thousand. The remaining balance of up to US$3.0 million remains payable upon the achievement of certain milestones based on the commencement and completion of clinical trials. Additional amounts paid will be classified as acquired patents and licenses and will be amortized over the estimated useful life of the licensed asset.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

14.	Contingencies, commitments and guarantees (continued):

The Company did not meet any of these milestones during the current year and does not currently expect to achieve any of the above milestones in fiscal years ended May 31, 2011 or 2012 and cannot reasonably predict when such milestones will be achieved, if at all.

The Company holds an exclusive world-wide license from the University of Manitoba (the "University") and Cancer Care Manitoba ("CCM") to certain patent rights to develop and sub-license certain oligonucleotide technologies. In consideration for the exclusive license of the patent rights, the University and CCM are entitled to an aggregate of 1.67% of the net sales received by the Company from the sale of products or processes derived from the patent rights and 1.67% of all monies received by the Company from sub-licenses of the patent rights. Any and all improvements to any of the patent rights derived in whole or in part by the Company after the date of the license agreement, being June 20, 1997, are not included within the scope of the agreement and do not trigger any payment of royalties.

The Company has not yet earned any revenue from the products covered under this agreement and, therefore, has not paid any royalties thereunder and cannot reasonably predict the timing and amount of any future payment. The Company does not expect to make any royalty payments under this agreement in fiscal years ended May 31, 2011 or 2012, and cannot reasonably predict when such royalties will become payable, if at all.

(c)

Guarantees:

The Company entered into various contracts, whereby contractors perform certain services for the Company. The Company indemnifies the contractors against costs, charges and expenses in respect of legal actions or proceedings against the contractors in their capacity of servicing the Company. The maximum amounts payable from these guarantees cannot be reasonably estimated. Historically, the Company has not made significant payments related to these guarantees.

The Company indemnifies its directors and officers against any and all claims or losses reasonably incurred in the performance of their service to the Company to the extent permitted by law. The Company has acquired and maintains liability insurance for its directors and officers. The fair value of this indemnification is not determinable.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

14.	Contingencies, commitments and guarantees (continued):

(d)

Indemnification on Arrangement:

Under the Arrangement (note 1(b)), the Company has agreed to indemnify Old Lorus and its directors, officers and employees from and against all damages, losses, expenses (including fines and penalties), other third party costs and legal expenses, to which any of them may be subject arising out of any matter occurring:

(i)

prior to, at or after the effective time of the Arrangement ("Effective Time") and directly or indirectly relating to any of the assets of Old Lorus transferred to the Company pursuant to the Arrangement (including losses for income, sales, excise and other taxes arising in connection with the transfer of any such asset) or conduct of the business prior to the Effective Time;

(ii)

prior to, at or after the Effective Time as a result of any and all interests, rights, liabilities and other matters relating to the assets transferred by Old Lorus to the Company pursuant to the Arrangement; and

(iii)

prior to or at the Effective Time and directly or indirectly relating to, with certain exceptions, any of the activities of Old Lorus or the Arrangement.

Subsequent to the release of the escrowed amount of $600 thousand in July 2008, the Company recorded a liability of $150 thousand, which it believes to be a reasonable estimate of the fair value of the obligation for the indemnifications provided at that time. This liability was reduced to $100 thousand in the current year resulting in a gain on sale of $50 thousand in the year ended May 31, 2010 (2009 - $450 thousand). The reduction in liability is the result of the passage of time and related reduction in risk associated with claims under the liability as there have been no claims under this indemnification to date. This amount is included on the consolidated balance sheets in accrued liabilities as at May 31, 2010.

(e)

Financing fees:

The Company has incurred approximately $200 thousand in fees subsequent to year end related to the financing in note 6(c) which will be paid despite the termination of the financing.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

14.	Contingencies, commitments and guarantees (continued):

(f)

Regulatory matter:

On October 31, 2008, the Company voluntarily delisted its common shares from trading on the NYSE Alternext US LLC (formerly the American Stock Exchange or AMEX). The Company was eligible to apply for deregistration from the Security Exchange Commission one year after delisting from the NYSE Alternext US LLC.

15.	Financial instruments:

Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

Cash and cash equivalents, short-term investments, other assets, accounts payable, accrued liabilities and promissory note payable:

Due to the short period to maturity of the financial instruments, the carrying values as presented in the consolidated balance sheets are reasonable estimates of fair value.

Financial instruments potentially exposing the Company to a concentration of credit risk consist principally of cash equivalents and short-term investments. The Company mitigates this risk by investing in high grade fixed income securities.

Assets measured at fair value on a recurring basis as of May 31, 2010 and May 31, 2009 were as follows:


2010	Level 1		Level 2		Level 3		Total

Assets:
Cash and cash equivalents	$	667	$	-	$	-	$	667
Short-term investments, consisting of guaranteed investment certificates		247		-		-		247

	$	914	$	-	$	-	$	914

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

15.	Financial instruments (continued):


2009	Level 1		Level 2		Level 3		Total

Assets:
Cash and cash equivalents	$	5,374	$	-	$	-	$	5,374
Short-term investments, consisting of guaranteed investment certificates		490		-		-		490

	$	5,864	$	-	$	-	$	5,864

16.	License agreement:

Effective April 8, 2008, the Company entered into a non-exclusive multinational license agreement with ZOR, formed as a subsidiary of Zoticon Bioventures Inc., to further develop and commercialize Virulizin® for human therapeutic applications.

Under the terms of the agreement, the Company received an upfront licensing fee of $100 thousand, was eligible to receive certain milestone payments totalling approximately US$10 million based on progress through financing and clinical development, and royalties on net sales that vary from 10% to 20% depending on the level of sales of Virulizin® achieved in those territories covered by the license and subject to certain other adjustments. ZOR will assume all future costs for the development of the licensed technology. In 2009, the Company received an additional payment of $178 thousand (US$150 thousand).

As described in note 13, on June 22, 2009, this license agreement was assigned to TEMIC as part of the Consideration for the repayment of the convertible debentures.

The Company also entered into a service agreement with ZOR to assist in the transfer of knowledge. Under this agreement, the Company agreed to provide ZOR with 300 hours of consulting service during a period of 18 months (the agreement expired in October 2009).

The initial fee of $100 thousand and a milestone payment of $178 thousand (US$150 thousand) were deferred under this arrangement and revenue was recognized based on the measure of progress toward completion of the technical support services under this contract based on the actual hours provided relative to the total number of hours required to be provided, applied to the total of these initial fee and non-contingent contractual payments related to the support services. At any time, the amount of cumulative revenue recognized would not exceed the cumulative amount of non-refundable payments received under the arrangement. All of the revenue received under this agreement has now been recognized.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

16.	License agreement (continued):

In addition, the Company acquired an equity interest in ZOR in exchange for a capital contribution of $2,500. As described in note 13, on June 22, 2009, as part of the agreement to repurchase the convertible debentures, the Company disposed of its interest in ZOR and assigned the licence agreement to TEMIC.

17.	Related party transactions:

In October 2009, the Company entered into a loan agreement with a member of its Board of Directors to borrow $1 million. The loan amount, which was received on October 6, 2009, was unsecured, evidenced by a promissory note and bears interest at the annual rate of 10%. The principal and interest were due in six months. The principal amount of $1.0 million was applied to subscribe for Units as part of the November 27, 2009 private placement.

In April 2010, the Company entered into a loan agreement with a company related to the same member as above of its Board of Directors to borrow $1 million. The loan amount, which was received on April 14, 2010, is unsecured, evidenced by a promissory note and bears interest at the annual rate of 10%. The principal and interest amount are due in six months. The funds will be used for general working capital purposes.

During the year ended May 31, 2010, the Company expensed consulting fees of nil to a director of the Company (2009 - $25 thousand; 2008 - $31 thousand). There was no amount payable at May 31, 2010 (2009 - nil; 2008 - $30 thousand).

This transaction was in the normal course of business and has been measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

See also note 18 for additional related party transactions.

LORUS THERAPEUTICS INC.

Notes to Consolidated Financial Statements (continued)

(Tabular amounts in thousands of Canadian dollars, except per share amounts)

Years ended May 31, 2010, 2009 and 2008

18.	Subsequent events:

On August 27, 2010, subsequent to the year end, due to unfavourable market conditions, the Company withdrew a previously announced equity issue and is proposing a shareholders' rights issue with a financing commitment for an investment of $4 million by one of the Company's directors, Mr. Herbert Abramson by way of standby purchase arrangements for the proposed rights offering such that the minimum gross proceeds of the proposed rights offering are $4 million. The Company expects the proposed investment to be made by October 31, 2010. Mr. Abramson is also providing the Company with interim financing by way of three $500 thousand monthly loans, the first of which was advanced on August 11, 2010. The loans are unsecured, have a six-month term (or the earlier of the closing of the rights issue) and bear interest at the annual rate of 10%. In addition, the loan due in October 2010 has been extended for an additional three months.